Welcome : Guest

Opexa Therapeutics, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Opexa Therapeutics, Inc., which is principally involved in Personalized Immunotherapy Business. Illustrated with 15 tables, the report showcases the company's recent news stories and events, key markets and market position as against its competitors operating in the industry.

Code: PCP-40383
Price: $750
Company Type: Public
Pages: 18
Date: June 2016
Market Data Tables: 15

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Immunology......3
Table 1: Immunology Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Dermatology, Gastroenterology, and Rheumatology......3
Multiple Sclerosis......4
Table 2: Multiple Sclerosis Disease Occurrence by Type Worldwide (2014) - Percentage Breakdown by Volume for Begin MS, Primary Progressive MS, Relapsing-Remiting MS, and Secondary Progressive MS......4
Table 3: Multiple Sclerosis Patient Care Expenditure by Category Worldwide (2014) - Percentage Breakdown by Value for Adaptations, Ambulatory Care, Disease Modifying Drugs, Early Retirement, Hospital Inpatient Care, Informal Care, Prescription and OTC Drugs, Services, Sick-leave and Redused Working Time, and Tests......5
Table 4: Relapsing-Remitting Multiple Sclerosis (RRMS) Market by Region Worldwide (2015) - Percentage Share Breakdown by Volume for European Union (EU), US, Rest of World (RoW)......6
Autologous Stem Cells......7
Table 5: Autologous Stem Cell Market by Disease Worldwide (2014) - Percentage Share Breakdown by Value for Infection, New Malignancy, Organ Failure, Primary Disease and Others......7
Clinical Trials......8
Table 6: Clinical Trials by Region Worldwide (2014) - Percentage Market Share Breakdown by Value for Africa, Asia, Australia, Canada, Europe, Mexico, South America, and United States......8
Tcelna (Imilecleucel-T)......9
Table 7: No. of Tcelna (Imilecleucel-T) Secondary Progressive Multiple Sclerosis Patients by Category in the US (2014) - Percentage Breakdown for Primary Progressive MS Patients, Relapsing-Remitting MS Patients, and Secondary-Progressive MS Patients......9
Allergy Immunotherapy......10
Table 8: Market Shares of Leading Allergy Immunotherapy Treatment Providers in the UK (2015) - Percentage Breakdown by Value for ALK, Allergopharma, Allergy Therapeutics, HAL Allergy, Leti/Novartis, Stallergenes, and Others......10
Table 9: Market Shares of Leading Bulk Extract Allergy Immunotherapy Manufacturers in the US (2015) - Percentage Breakdown by Value for ALK, Greer Laboratories, Inc., HollisterStier LLC and Others......11
Immunology/ Immunoglobulin (IG)......12
Table 10: Market Shares of Leading Immunology/ Immunoglobulin Providers in the US (2015) - Percentage Breakdown by Value for Baxter International Inc., CSL Limited, Grifols, S.A., and Others......12
Relapsing-Remitting Multiple Sclerosis (RRMS)......13
Table 11: Market Shares of Leading Drug Brands for Relapsing-Remitting Multiple Sclerosis (RRMS) Worldwide (2015) - Percentage Breakdown by No. of Patients for Avonex, Betaseron, Copaxone, Gilenya, Laquinimod, Rebif, Tysabri, and Others......13
Table 12: Market Shares of Leading Drug Brands for Relapsing-Remitting Multiple Sclerosis (RRMS) Worldwide (2015) - Percentage Breakdown by Value for Avonex, Betaseron, Copaxone, Gilenya, Laquinimod, Rebif, Tysabri, and Others......14
Immunohematology......15
Table 13: Market Shares of Leading Immunohematology Product Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for Bio-Rad Laboratories, Inc., Grifols, S.A., Immucor, Inc., Ortho Clinical Diagnostics, and Others......15
Multiple Sclerosis Therapeutics......16
Table 14: Market Shares of Leading Multiple Sclerosis Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for Biogen Idec, Novartis AG, Sanofi S.A., and Others......16
Orphan Disease Therapeutics......17
Table 15: Market Shares of Leading Orphan Disease Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for Pfizer, Inc., Sanofi S.A., and Others......17